Cargando…
Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection
There is a substantial need for novel therapeutics to combat the widespread impact caused by Crytosporidium infection. However, there is a lack of knowledge as to which drug pharmacokinetic (PK) characteristics are key to generate an in vivo response, specifically whether systemic drug exposure is c...
Autores principales: | Arnold, Samuel L. M., Choi, Ryan, Hulverson, Matthew A., Schaefer, Deborah A., Vinayak, Sumiti, Vidadala, Rama S. R., McCloskey, Molly C., Whitman, Grant R., Huang, Wenlin, Barrett, Lynn K., Ojo, Kayode K., Fan, Erkang, Maly, Dustin J., Riggs, Michael W., Striepen, Boris, Van Voorhis, Wesley C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853285/ https://www.ncbi.nlm.nih.gov/pubmed/28541457 http://dx.doi.org/10.1093/infdis/jix247 |
Ejemplares similares
-
Bumped kinase inhibitor 1369 is effective against Cystoisospora suis in vivo and in vitro
por: Shrestha, Aruna, et al.
Publicado: (2019) -
P-Glycoprotein–Mediated Efflux Reduces the In Vivo Efficacy of a Therapeutic Targeting the Gastrointestinal Parasite Cryptosporidium
por: Arnold, Samuel L M, et al.
Publicado: (2019) -
Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of Cryptosporidiosis
por: Hulverson, Matthew A., et al.
Publicado: (2023) -
Reduced treatment frequencies with bumped kinase inhibitor 1369 are effective against porcine cystoisosporosis
por: Shrestha, Aruna, et al.
Publicado: (2020) -
Screening of the Pathogen Box for inhibitors with dual efficacy against Giardia lamblia and Cryptosporidium parvum
por: Hennessey, Kelly M., et al.
Publicado: (2018)